Tuberculosis is the predominant infection in systemic sclerosis: thirty-year retrospective study of serious infections from a single centre-Reference-Cited by-同舟云学术

Tuberculosis is the predominant infection in systemic sclerosis: thirty-year retrospective study of serious infections from a single centre

Published:2024-08-24 Issue: Volume: Page:
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Gollarahalli Patel Abhishek^ORCID,Ahmed Sakir^ORCID,Parida Jyoti Ranjan^ORCID,Pattanaik Sarit Sekhar^ORCID,Gupta Latika^ORCID,Aggarwal Amita^ORCID,Lawrence Able^ORCID,Misra Durga Prasanna^ORCID,Nath Alok^ORCID,Hashim Zia^ORCID,Khan Ajmal^ORCID,Mishra Richa^ORCID,Ravindra Akshatha^ORCID,Mohindra Namita^ORCID,Jain Neeraj^ORCID,Agarwal Vikas^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00296-024-05688-0.pdf

Reference43 articles.

1. Barahona-Correa JE, De la Hoz A, López MJ, Garzón J, Allanore Y, Quintana-López G (2020) Infections and systemic sclerosis: an emerging challenge. Revista Colombiana de Reumatología (English Edition) 27:62–84. https://doi.org/10.1016/j.rcreue.2019.12.004

2. Rongioletti F, Ferreli C, Atzori L, Bottoni U, Soda G (2018) Scleroderma with an update about clinico-pathological correlation—Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia1 53(2):208–215. https://doi.org/10.23736/s0392-0488.18.05922-9

3. Bussone G, Berezné A, Mouthon L (2009) Complications infectieuses de la sclérodermie systémique. La Presse Médicale 38(2):291–302. https://doi.org/10.1016/j.lpm.2008.11.003

4. Allanore Y, Denton CP, Krieg T, Cornelisse P, Rosenberg D, Schwierin B, Matucci-Cerinic M (2016) Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the digital ulcer outcome registry: a prospective, observational cohort. Ann Rheum Dis 75(9):1736–1740. https://doi.org/10.1136/annrheumdis-2016-209481

5. Khanna D, Lin CJ, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963–974. https://doi.org/10.1016/S2213-2600(20)30318-0